Global Anti-Obesity Drugs Market Research Report 2022 - Market Size, Current Insights and Development Trends

The Anti-Obesity Drugs market has witnessed a growth from USD XX million to USD XX million from 2017 to 2022. With a CAGR of X.X%, this market is estimated to reach USD XX million in 2029.

The report focuses on the Anti-Obesity Drugs market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19.

Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market. Moreover, customer preference analysis, market dynamics (drivers, restraints, opportunities), new product release, impact of COVID-19, regional conflicts and carbon neutrality provide crucial information for us to take a deep dive into the Anti-Obesity Drugs market.

Major Players in the Anti-Obesity Drugs market are:
Zydus Cadila
F. Hoffmann-La Roche AG
Bayer AG
Alizyme
Novo Nordisk AS
Norgine BV
GlaxoSmithKline PLC
Eisai Co. Ltd
Currax Pharmaceuticals LLC
Arena Pharmaceuticals Inc.
Zafgan
Orexigen Therapeutics
Rhythm Pharmaceuticals
Merck & Co. Inc.
Pfizer Inc.
Vivus Inc.
Takeda Pharmaceuticals
Bristol-Myers Squibb

On the basis of types, the Anti-Obesity Drugs market is primarily split into:
Peripherally Acting Drugs
Centrally Acting Drugs

On the basis of applications, the market covers:
Prescription Drugs
OTC Drugs

Major Region

s or countries covered in this report:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others

Years considered for this report:

Historical Years:

2017-2021

Base Year:

2021

Estimated Year:

2022

Forecast Period:

2022-2029

Frequently Asked Questions